Meyka Pro is live. Get 50% off your first 3 months.Get Started →
Meyka Pro banner
Parabilis Medicines, Inc.

Parabilis Medicines, Inc. (PBLS) Stock Overview

Explore Parabilis Medicines, Inc.’s financial performance, market position, analyst ratings, and future outlook.

PBLS●NASDAQ
HealthcareBiotechnology
$37.07
$1.40(3.92%)
U.S. Market opens in 47h 7m

Parabilis Medicines, Inc. (PBLS)

Meyka AI Score

Z

Key Financials

Market Cap4.3B
P/E RatioN/A
EPS (TTM)$-0.88
ROEN/A
Fundamental Analysis

AI Price Forecasts

1 Month$43.00
3 Months$71.82
1 Year Target$103.72

PBLS Stock Analysis & Investment Overview (NASDAQ)

Our AI-powered analysis of Parabilis Medicines, Inc. (NASDAQ: PBLS) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B, Parabilis Medicines, Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.

The current technical analysis of PBLS on the NASDAQ shows an RSI of 65.23, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $103.72 for the NASDAQ listing.

Key metrics behind Parabilis Medicines, Inc.'s NASDAQ-traded stock include a P/E ratio of N/A and a market capitalization of 4.3B. Combined with our AI analysis, these give both institutional and retail investors a clear view of PBLS on the NASDAQ.

Price Performance (NASDAQ: PBLS)

1-Day Change
3.92%
5-Day Change
2.40%
1-Month Change
19.005%
3-Month Change
85.35%
6-Month Change
85.35%
Year-to-Date (YTD) Change
85.35%
1-Year Change
85.35%
3-Year Change
85.35%
5-Year Change
85.35%
All-Time (Max) Change
85.35%

Contact Information

http://www.parabilismed.com
NaN
30 Acorn Park Dr, Cambridge, MA, 02140

Company Facts

1,450 Employees
IPO DateJun 10, 2026
CountryUS
Actively Trading

Frequently Asked Questions